News & Analysis on Clinical Trial Services & Contract Research And Development
BioProgress, which makes cellulose based XGEL films for coating tablets and capsules, has signed an agreement with a contract manufacturing organisation to accelerate the installation of its own film manufacturing capacity.
Exiqon has launched two new ProbeLibrary expression analysis kits, covering the genomes of Arabidopsis thaliana and Drosophila melanogaster, the most widely used models in disease process and drug target studies.
Merck & Co has licensed rights to a novel drug for the treatment of stroke, developed by Japan's Ono Pharmaceutical, in the hope of developing what would be only the second drug to treat the disease.
Argonaut Technologies has announced the introduction of EVOLUTE ABN (Acidic Basic Neutral), a product that extracts drugs from biological fluids through improved phase extraction.
Galapagos Genomics are set to receive additional milestone payments of up to $40 million (€30.9 million) after its osteoporosis discovery program with Wyeth Pharmaceuticals resulted in the US drug gaints successfully selecting novel drug targets for...
Nitto Denko and antisense specialist Isis Pharmaceuticals have jointly developed a new solid support for the manufacture of oligonucleotides that promises to reduce the high manufacturing costs for this type of drug.
Active-Pak Automation claims that companies installing its dessicant sachet dispensing systems can achieve cost savings of up to 40 per cent compared to systems based on canisters, offsetting the capital costs of installing the machinery.
With just a few weeks to go before the introduction of India's new patent regime - which will increase protection to include product as well as process patents - a group of government Ministers is calling for a waiver that would allow compulsory...
Sweden's Cellectricon has launched a new microfluidic chip product that promises to speed up the screening of drugs that interact with ion channels, an important drug target that make up around 15 per cent of all medicines on the market.
The first ever-manufacturing agreement for a drug based on small interfering RNA emphasises the potential of this pioneering therapeutic approach, which could be a fertile stamping ground for contract manufacturers.